AACR.org|

Join us in Atlanta during the AACR Annual Meeting 2019
for this 5K to support lifesaving cancer research.

Gilteritinib provides a new treatment option for certain patients
whose AML tests positive for a mutation in the FLT3 gene.

Diagnosed with Hodgkin lymphoma at 24,
Mia found what was important to her.

Larotrectinib is the first therapeutic approved for use based
on a tumor biomarker rather than where the cancer originated.

In February, join with the AACR to find better ways to
prevent and treat gallbladder cancer and bile duct cancer.

We've distributed more than $316 million
in cancer research funding since 2001

Our Research

We support all forms of research from basic and translational to clinical and population science on the more than 200 types of cancer.

Our People

The AACR's membership – more than 40,000 strong – features the world's leading cancer researchers and includes 40 Nobel laureates.

Our Impact

Our members have been at the forefront of every major advance in cancer research for the last 110+ years.

Donate

Make an Impact: Give to the AACR Foundation, where 88 cents of every dollar we raise supports innovative cancer research.

Donate

Volunteer

Use Your Talents: Help to raise money for cancer research by participating in our events or by creating an event of your own.

Volunteer

Take Action

Raise Your Hand: Get involved with the AACR's efforts to support, advocate for, and communicate the importance of cancer research.

Take Action

Join us in Atlanta during the AACR Annual Meeting 2019
for this 5K to support lifesaving cancer research.

Gilteritinib provides a new treatment option for certain patients
whose AML tests positive for a mutation in the FLT3 gene.

Diagnosed with Hodgkin lymphoma at 24,
Mia found what was important to her.

Larotrectinib is the first therapeutic approved for use based
on a tumor biomarker rather than where the cancer originated.

In February, join with the AACR to find better ways to
prevent and treat gallbladder cancer and bile duct cancer.

We've distributed more than $316 million
in cancer research funding since 2001

Our Research

Our People

Our Impact

Donate

Volunteer

Take Action

Cancer Connections

Tell Your Cancer Story

Gallbladder and Bile Duct Cancer Awareness

Cancer Today: Practical Knowledge. Real Hope.

Cancer Research Catalyst

Cancer Survivor Journeys

National Cancer Prevention Month

Join us in Atlanta during the AACR Annual Meeting 2019 for this 5K to support lifesaving cancer research.

Gilteritinib provides a new treatment option for certain patients whose AML tests positive for a mutation in the FLT3 gene.

Diagnosed with Hodgkin lymphoma at 24, Mia found what was important to her.

Larotrectinib is the first therapeutic approved for use based on a tumor biomarker rather than where the cancer originated.

In February, join with the AACR to find better ways to prevent and treat gallbladder cancer and bile duct cancer.

We've distributed more than $316 million in cancer research funding since 2001

Our Research

Our People

Our Impact

Donate

Volunteer

Take Action

Cancer Connections

Tell Your Cancer Story

Gallbladder and Bile Duct Cancer Awareness

Cancer Today: Practical Knowledge. Real Hope.

Cancer Research Catalyst

Cancer Survivor Journeys

National Cancer Prevention Month

Join us in Atlanta during the AACR Annual Meeting 2019
for this 5K to support lifesaving cancer research.

Gilteritinib provides a new treatment option for certain patients
whose AML tests positive for a mutation in the FLT3 gene.

Diagnosed with Hodgkin lymphoma at 24,
Mia found what was important to her.

Larotrectinib is the first therapeutic approved for use based
on a tumor biomarker rather than where the cancer originated.

In February, join with the AACR to find better ways to
prevent and treat gallbladder cancer and bile duct cancer.

We've distributed more than $316 million
in cancer research funding since 2001